Reliance Global Group announced that it has entered into a non-binding term sheet to acquire a controlling interest in Enquantum. In addition, in connection with the term sheet, On January 15, 2026, Reliance executed a secured promissory note as an advance of the initial funding under a definitive agreement, if executed. The Promissory Note is secured by all of the assets of Enquantum and payable within 60 days of its issuance date if a definitive agreement is not entered into. If a definitive agreement is entered into, the balance due under the Promissory Note will be applied against the first two payment milestones.

1/22 10:00

Reliance Global Changes NASDAQ Ticker to EZRA

Reliance Global Group announced that its ticker symbol on the NASDAQ Capital Market will change from "RELI" to "EZRA", effective at the open of trading on Monday, January 26. The Company's common stock will continue to be listed on NASDAQ, and its CUSIP number will remain unchanged. The company said, "The ticker symbol change is intended to better reflect the Company's strategic evolution, including the formation of EZRA International Group, a new division focused on acquiring controlling stakes and accelerating the growth of breakthrough technology companies, with an initial emphasis on businesses operating across sectors such as cybersecurity, artificial intelligence and data analytics, FinTech and InsurTech, as well as MedTech and digital health. This strategic evolution is already underway through the Company's recently announced plan to acquire a majority stake in Scentech, an artificial intelligence diagnostics company developing non-invasive, breath-based disease-detection technologies. The proposed Scentech transaction, structured around clinical, regulatory, and operational milestones, represents the Company's first anticipated acquisition under EZRA International Group and reflects the Company's intention to pursue high-impact, technology-driven opportunities with significant long-term upside potential."

1/7 08:40

Reliance Global to Acquire Majority Stake in Scent Medical Technologies

Reliance Global announced that it has entered into a non-binding term sheet to acquire a majority equity position of Scent Medical Technologies. Scentech is a diagnostics company developing artificial intelligence technologies designed to identify disease-associated molecular signatures in human breath. Scentech's product candidates are under development and have not yet been clinically validated or approved for commercial use. Any potential clinical or commercial outcomes remain subject to successful clinical validation and applicable regulatory clearances or approvals. The proposed transaction is expected to become the first asset within Ezra International Group, Reliance's newly established division focused on strategic investments in technology-driven companies.

1/5 08:50

Reliance Global Forms EZRA International Group to Acquire High-Tech Companies

Reliance Global announced the unanimous Board approval for its formation of EZRA International Group, a new division focused on acquiring controlling stakes and accelerating growth of high-tech Israeli companies, with an initial focus on the Cybersecurity, AI & Data Analytics, FinTech & InsurTech, as well as MedTech & Digital Health sectors. Through this initiative, the company said it intends to pursue a structured path toward value realization, which may include public listings, strategic spin-offs, or other monetization events designed to maximize shareholder value. "We believe the current market capitalization of the Company does not fully reflect the intrinsic value and historic cash flow of our insurance operations," said Ezra Beyman, CEO of Reliance Global Group.

12/29 08:50

Reliance Global Completes Sale of Subsidiaries to Optimize Balance Sheet

Reliance Global Group finalized the sale of two of its subsidiaries, Employee Benefits Solutions and U.S and Benefits Alliance, two non-core agencies located in Cadillac, Michigan. The transaction is part of a comprehensive balance sheet rationalization program, intended to enhance the Company's ability to execute on new initiatives. Overall, the Company has been engaged in a strategy to focus efforts on areas that the Company believes will produce better outcomes. Since acquiring U.S. Benefits Alliance and Employee Benefits Solutions in 2019, Reliance has selectively integrated portions of the businesses that aligned with its long-term, technology-forward strategy into its core RELI Exchange platform. The transaction reflects the sale of only the remaining non-core components of those businesses, while the strategic elements previously integrated into Reliance's core operations remain part of the Company's ongoing growth initiatives. The Company will use 50% of the net proceeds to reduce debt and the balance will be reinvested in strategic business initiatives.

Show More Events

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。